Investor Presentation

GPT Healthcare Limited Regd. Office: GPT Centre, JC-25, Sector III, Salt Lake, Kolkata – 700 106, India CIN : L70101WB1989PLC047402 Phone : +91-33-4050-7000, Email : info@gptgroup.co.in , Visit us: www.gptgroup.co.in GPTHEALTH/CS/SE/2026-27 November 5, 2026 The Department of Corporate Services National Stock Exchange of India Limited BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E), Dalal Street Mumbai - 400 051 Mumbai – 400001 Scrip Symbol: GPTHEALTH Scrip Code: 544131 ISIN: INE486R01017 Dear Sir/Madam Sub: Submission of Investor Presentation on Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2026: In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a copy of Investor Presentation on Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2026 for dissemination to general public and Investors. Kindly take the aforesaid information on record and oblige. Thanking You, Yours sincerely, For GPT Healthcare Limited Ankur Sharma Company Secretary and Compliance Officer M. No A31833 Encl. As Above. GGPPTT HHEEAALLTTHHCCAARREE LLIIMMIITTEEDD Investor Presentation Q2 & H1FY27 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by GPT Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contractor binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guaranteeing of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Key Highlights of the Q2 & H1FY27 ➢ ARPOB grew 7.1% YoY to ₹40721, reflecting improved realisations supported by a stronger clinical offering, a favourable speciality mix and enhanced operational efficiencies. Network occupancy in Q2FY27 has improved from 47.4% to 50.3% (59.8% excluding Raipur) indicating better utilisation of the hospital network. ➢ During H1 FY27, mature hospitals continued to demonstrate resilient operating performance, contributing ₹261.8 crore in revenue, ₹56.0 crore in EBITDA and ₹28.1 crore in PAT, with an EBITDA margin of approximately 21%.ILS Dum Dum remained the largest revenue contributor, reflecting its strong patient volumes and established clinical presence. ➢ ILS Raipur achieved NABH accreditation within its first year, performed its first TAVI procedure and liver transplant in Q2 FY27, and completed 11 renal transplants within a year. ➢ ILS Agartala Oncology program continues to gain strength with over 3200 radiation therapy procedures through its Linear Accelerator facility, and over 1000 PET scans in just over a year. ➢ ILS Salt Lake has crossed 850 robotic surgeries, while ILS Howrah, equipped with the MAKO robotic system, is nearing 100 robotic procedures. ➢ The upcoming 155-bed tertiary care hospital in Jamshedpur is progressing as planned and is expected to commence operations in March/April 2027. ➢ Building on its established presence in Eastern India, strong clinical capabilities and disciplined expansion strategy, the company is targeting long-term ROCE and ROE of approximately 25%, while evaluating additional greenfield expansion opportunities. Company Overview GPT Healthcare Limited is a fast-growing hospital platform in Eastern India, operating five, tertiary-care hospitals located within densely populated residential areas. 719 122 Beds- total capacity Full time consultants Designed around a proximity-based model, its hospitals offer the reassurance of advanced medical care almost at the doorstep—ensuring high accessibility for patients while enabling strong control over clinical quality, operating standards, and long-term returns on capital. 900+ Led by Dr. Om Tantia, the company follows a disciplined, 642 Robot-enabled Surgeries capital-efficient operating model with advanced capabilities Visiting consultants across oncology, cardiology, renal transplants, and robotic surgeries. With a clearly defined plan to scale to a 1,000-bed network by FY2027, supported by integrated diagnostics and a strong regional brand, GPT Healthcare is well positioned to capture NABH & NABL Optimally sized rising healthcare demand, enhance profitability, and deliver accreditations Hospitals sustained value to investors. Financial Snapshot Financial Snapshot for Q2 & H1FY27 Q2 FY27 Revenue from Operations EBITDA & EBITDA Margin PAT & PAT Margin Rs 135.6 Cr Rs 29.8 Cr Rs 15.4 Cr (Overall – 21.5% Margin, (11.1% Margin (Raipur – Rs 9.0 Cr, Mature – Rs 126.6 Cr 23.9% YoY) 45.2% YoY) 14.1% YoY ARPOB Occupancy Rate % Dum Dum Rs 40,721 50.3% Raipur – 16.5%, Mature – 59.8% Agartala H1 FY27 Salt lake Howrah Jamshedpur Revenue from Operations EBITDA & EBITDA Margin PAT & PAT Margin Rs 28.1 Cr Rs 261.8 Cr Rs 56.0 Cr Raipur (10.5% Margin (Raipur – Rs 19.6 Cr, Mature – Rs 242.2 Cr (Overall – 21.0% Margin, 53.9% YoY) 15.8% YoY) 30.3 % YoY) Existing hospitals Upcoming Hospitals Salt lake Jamshedpur ARPOB Occupancy Rate % Dum Dum Howrah Rs.41,490 47.9% Agartala Other proposed Raipur – 17.0%, Mature – 56.7% Raipur Hospitals *planned hospital 6 ARPOB- Average Rate Per Occupied bed ; ALOS- Average length of stay Hospital-wise performance for Q2 & H1 FY27 Salt lake Hospital Agartala Hospital Dum-Dum Hospital Howrah Hospital Raipur Hospital West Bengal Tripura West Bengal West Bengal Chhattisgarh Year of 2000 2011 2013 2019 2025 commissioning Q2 FY27 H1FY27 Q2 FY27 H1FY27 Q2 FY27 H1FY27 Q2 FY27 H1FY27 Q2 FY27 H1FY27 Bed capacity 85 205 155 116 158 (No of beds) Revenue (INR Cr) 22.2 44.0 39.7 74.8 45.1 84.8 19.7 38.5 9.0 19.6 Occupancy Rate 68.4% 65.4% 53.7% 49.6% 73.3% 69.4% 46.4% 45.8% 16.5% 17.0% ARPOB (INR) 41,480 43,284 39,154 40,254 43,125 [Showing first 8,000 characters — download PDF for full document]